Member Area

Farmavita.Net - Pharmaceutical Licensing Network

Saturday
Jan 31st
Home arrow Farmavita.Net Journal
Farmavita.Net Journal
Print E-mail
Market Report

publisherlogo.gif

Global Ophthalmology Devices Market

Global ophthalmology devices and drugs market is witnessing a significant growth due to the increasing incidence and prevalence of eye related disorders such as presbyopia, macular degeneration, and diabetic retinopathy among the aging population. With the introduction of ophthalmic devices equipped with sophisticated technologies, people are increasingly opting for ophthalmic surgeries to correct their eye related disorders.

Read more...
 
Print E-mail
Press Release

Second annual Pharmaceutical Risk-Sharing  & Value-based Pricing and Reimbursement Models

Bratislava, 15-16 th April 2010

Not being a specialist in the area of Risk-Sharing & Value-based Pricing this event was an excellent introduction for me. Meeting P&R experts from some of the most important pharma companies in the world as well as hearing their detailed presentations was a really good experience.

The event was splendidly organised by Next Level Pharma in Trend Hotel,Bratislava, SK, near the city centre, which was an excellent location. The overall impession was ruined only by a bad weather which did not allow a proper sightseeing of the city and disturbed air traffic which made problems to the return flight of most participants. 

Read more...
 
Print E-mail
Market Report

globaldata_logo.jpg

Nonalcoholic Steatohepatitis - Drug Pipeline Analysis and Market Forecasts to 2016

GlobalData, the industry analysis specialist's new report, "Nonalcoholic Steatohepatitis (NASH) - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global nonalcoholic steatohepatitis market. The report identifies the key trends shaping and driving the global nonalcoholic steatohepatitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global nonalcoholic steatohepatitis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Read more...
 
Print E-mail
Market Report

globaldata_logo.jpg

HIV/AIDS - Drug Pipeline Analysis and Market Forecasts to 2016

GlobalData's report, "HIV/AIDS - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global HIV/AIDS market. The report identifies the key trends shaping and driving the global HIV/AIDS market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders.

Read more...
 
Print E-mail
Press Release

datamonitor_logo.gif

GlaxoSmithKline: H1N1 hype unfounded as UK caps vaccine order

The UK government has capped its order of the H1N1 vaccine from GlaxoSmithKline. Following poor uptake of the vaccine in several European markets, the UK Department of Health has opted to limit its H1N1 contract with GlaxoSmithKline to 34.8 million doses. Despite the media hype surrounding the influenza outbreak, the mild course of the pandemic and negative public opinion of the vaccine means that its commercial impact will be significantly reduced.

Read more...
 
Print E-mail
Market Report

publisherlogo.gif

Diagnostic ECG Market (2009 - 2014)

The global diagnostic ECG market is categorized into three submarkets: the rest systems the stress systems and holter systems. These systems are used to measure the electrical activity of the heart. Amongst the three systems, rest system is the most widely-used diagnostic tool. The global market for rest system is expected to grow at a CARG of 9.6% from 2009 to 2014.

Read more...
 
Print E-mail
Market Report

publisherlogo.gif

In-Vitro Diagnostics (IVD) Market in BRIC (2010 - 2014)

The IVD markets of BRIC economies offer immense growth opportunities due to the increasing healthcare budgets in these nations, along with the increasing number of private corporate hospitals, and the rising income levels backed by a huge, untapped population bases.

Read more...
 
Print E-mail
Life Science Article

DIABETES III: A CAUSE OF ALZHEIMER’S DISEASE

INTRODUCTION

Type III diabetes also known as hybrid or double diabetes is a new and dangerous phenomenon. It is found that type III Diabetes affects brain insulin levels, and appears to be one of the major causes of Alzheimer's disease . Insulin receptors in the brain are sensitive to particles known as ADDL's.

Read more...
 
Print E-mail
Market Report

datamonitor_logo.gif

Benchmarking the Pharmaceutical Market by Drug Delivery to 2014

Drug delivery can play an important role at all stages of a drug's lifecycle and has become an ever present feature in the business model of the leading pharmaceutical companies. Using the PharmaVitae Explorer database, the report provides an in depth sales analysis of the specific routes of administration driving the pharmaceutical market out to 2014.

Read more...
 
Print E-mail
Company Report

datamonitor_logo.gif

Pharmaceutical Licensing Overview - Risk-aversion breeds creativity as externalization intensifies

Big Pharma continues to restructure its internal R&D departments as part of widespread cost-cutting measures to help reduce the impact of the impending 2011 patent cliff. To fill pipeline voids with new products, companies continue to make acquisitions and form partnerships with small pharma, biotech companies and academia, although the relationships between each are becoming increasingly dynamic.

Read more...
 
Print E-mail
Market Report

datamonitor_logo.gif

Pharmaceutical Key Trends 2010 - The patent cliff dominates but growth opportunities remain

Pharma faces a number of key resistors to growth including the impending 2011 patent cliff which is set to erode $78 billion in global branded sales from drugs facing patent expiry over the 2010/14 period (plus $32 billion from continued erosion of already expired brands). Price cuts, reimbursement restrictions and growing regulatory pressure are further set to limit sales growth going forward.

Read more...
 
Print E-mail
Market Report

publisherlogo.gif

U.S. Preterm Infant Care Market

Preterm infant care forms a significant part of the pediatric healthcare market in the U.S. as preterm births are one of the leading causes of infant mortality in the country. One in every eight births in the U.S. are preterm, and the condition is on an alarming rise due to factors such as induced fertility, labor treatments, poor prenatal care, inappropriate maternal age, obesity, and smoking.

Read more...
 
Print E-mail
Press Release

sv-itouch.jpg

Sales Vision Road Show Beograd - a great expirience

The first iPhone Pharma CRM application in the world was shown in Belgrade on Sales Vision Road Show, senior management event which gathered more than 50 delegates from pharma world of Serbia, Croatia and Bosnia and Herzegovina. Sales Vision Road Show is going on in other cities across Europe like in London, Bratislava, Bucurest etc.

Read more...
 
Print E-mail
Press Release

datamonitor_logo.gif

Big pharma struggles to benefit from increased CVD drug usage

London - Pharmaceutical companies will struggle to profit from the cardiovascular disease (CVD) market over the next decade despite growing drug usage, according to Datamonitor. New research* by the independent business analyst predicts that the CVD pharma market will grow from $99bn in 2008 to $107bn in 2018. Patent expiries and generic competition will have a major impact and Datamonitor expects AstraZeneca and Novo Nordisk to emerge as the only major CVD pharma companies to generate positive sales growth over the period.

Read more...
 
Print E-mail
Press Release

datamonitor_logo.gif

AstraZeneca deal lifts Rigel's arthritis drug out of development uncertainty

Having signed a license agreement with AstraZeneca, Rigel has boosted the prospects for R788, its RA drug. However, Phase III trials must address certain safety signals and reassure physicians of its efficacy in key patient populations. Prominent product differentiation will also be vital for the drug to compete with Pfizer's JAK inhibitor, which is set to reach the market two years ahead of it.

Read more...
 
Print E-mail
Business for Sale

strategic_moves.jpg

Lacerta BioCapital

Lacerta BioCapital, a member of Farmavita.Net, invests in sound, stable companies in promising Life Science segments with attractive futures (e.g., sustained positive cash flow; value increase potential of at least 20% p.a.; growth potential either organically or through acquisition; etc.). Our target companies have a sound customer base with a well balanced product portfolio. We aim to have a total investment budget of approximately €300 million (including credit capital), to be invested in around 10-15 Life Science companies.

Please contact us for introduction to Lacerta BioCapital. 

Read more...
 
Print E-mail
Press Release

datamonitor_logo.gif

New hope for Javelin's pain candidate but safety concerns remain

An external review of Phase III data for Javelin Pharmaceuticals' Ereska has found previously negative top-line results for its primary endpoint to be statistically significant. While the findings offer renewed hope for the company, ketamine's association with drug abuse and its well-documented hallucinatory effects represent key weaknesses in the market place, despite Ereska's proven efficacy.

Read more...
 
Print E-mail
Market Report

datamonitor_logo.gif

Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis population

Datamonitor expect osteoarthritis prevalence to grow by over 10 million by 2020, owing mainly to an aging population. In the near-term the approach to treatment will remain constant, with improved side-effects dominating the unmet needs. However, therapies which target the underlying causes of osteoarthritis have the potential to reshape osteoarthritis treatment.

Read more...
 
Print E-mail
Press Release

datamonitor_logo.gif

Pfizer's novel NGF pain drug is potential game changer

Phase II clinical trials of tanezumab in osteoarthritis, chronic low back pain and interstitial cystitis have demonstrated the drug's analgesic efficacy across these three chronic pain settings. Despite safety concerns and a high price point, Datamonitor expects tanezumab to enjoy a significant first-in-class advantage in a potentially lucrative novel area of pain therapy.

Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Results 172 - 190 of 557
Advertisement

Featured Partners

 medcommeu15_150x150.gif  
150-x-150controlled.jpg
2015-pmr-banner-150x150.gif  
barcelona2015_150x150_v2.gif 
150x150.jpg 

p-128-150x150.jpg  
inls05_150x150.jpg 
meddevproc15_150x150.gif 
medaff15a_150x150.gif 
150x150copd.jpg  
pharmacommex_150x150_farmavitar.jpg  

Follow us on:




Join our LinkedIn Group

BabelFish Translator




Click Flag for Translation

Who's Online

We have 17 guests online

Farmavita.Net RSS News


Reports

rbdl0002_innovations-in-inj.gif 

Events

2015-pmr-canada-banner-150x150.gif

Reports

rbhc0264_privatehealthcare.gif 

REPORTS

farmavita_research-store.gif